Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Ear...
Main Author: | Lalit S Raut |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2015-01-01
|
Series: | South Asian Journal of Cancer |
Subjects: | |
Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2015;volume=4;issue=1;spage=38;epage=40;aulast=Raut |
Similar Items
-
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
by: Chen EC, et al.
Published: (2018-06-01) -
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
by: Mayer LD, et al.
Published: (2019-05-01) -
The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
by: Abdullah M. Alrajhi, et al.
Published: (2019-10-01) -
AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
by: Kristin L. Koenig, et al.
Published: (2020-07-01) -
Assessment of oxidative stress in acute myeloid leukemia
by: Esfahani A, et al.
Published: (2011-02-01)